Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Working Towards a Sustainable Future for the NHS

Working Towards a Sustainable Future for the NHS

An interview with Jennifer Lee, Director of Market Access and Advocacy at Janssen UK, the pharmaceutical company of Johnson & Johnson, discussing the importance of innovation in the private sector and making new technologies available to the NHS.

How are Janssen working to ensure the future of the NHS? Do you think the current system is sustainable?

The current healthcare system is not sustainable, and I think most people would agree with that. You only need to look at the rising cost of healthcare globally and the aging population in the western world to understand that the current system isn’t sustainable long-term.

Image Credit: sheff / Shutterstock

Traditionally, companies like Janssen were seen only as suppliers of the healthcare system, but that’s starting to change. We’re seeing more and more joint working initiatives and partnerships between industry, academia, patient groups, and the clinical community.

We’re interested in partnering with the NHS because they are our main customer, so if the NHS isn’t sustainable, we as a business are not sustainable – and this will prevent us from getting our medicines to the patients who need them.

One of the ways we at Janssen are helping is by making sure our medicines fit into new models of care. We’re also trying to revolutionize the medicines we develop for the NHS.

Traditionally, pharmaceutical companies looked to develop medicines that target the most severe stages of a disease, because it is easier to prove that the drug has a significant effect in these patients.

We can no longer treat diseases when a patient becomes severely ill. It’s expensive and is the reason that the NHS can no longer afford to provide the same level of service as it once could. That’s why we’re now investing in drugs that act prophylactically. We need to start thinking about living with disease, rather than dying of it.

Prophylaxis is not a new concept, just look at how long we’ve been vaccinating against infectious disease! We now need to take this approach with non-communicable diseases.

The NHS is currently facing extreme economic hardship. What steps are Janssen taking to reduce this?

For the NHS to become sustainable, we need to deliver healthcare in a completely different way. For us, this means moving away from just being a provider of pills and moving towards personalized care and prevention.

Image Credit: Manop_Phimsit / Shutterstock

Before the human genome project, for example, all blockbuster drugs such as statin were developed to give to the entire eligible patient population.

At Janssen, we are now looking to develop highly targeted, specific, personalized medicines that are much more sophisticated and used in a much smaller population of patients – to ultimately help improve outcomes.

This is only part of the solution. The amount of data collated in the UK’s health system is enormous and we’re working on initiatives that will harness this data to provide key insights.

For instance, by analyzing all of the interactions a patient has had with the healthcare system could allow doctors to tailor their treatment plan and decide which interventions to use based on other patients with a similar medical history.

This could allow clinicians within the NHS to develop more of an understanding of which drugs work in which patients, based on their genotype and phenotype. It could also save money and allows the NHS to become more efficient. They would be paying for patient outcomes, rather than the treatment itself.

We want our medicines to do what they say on the tin. We want the NHS to be able to identify cases where what we observe in clinical trials differs from real-life. It’s as simple as not charging the NHS if the treatment isn’t effective in the patient cohorts that it’s designed for.

This is called an outcomes-based guarantee, and it’s already in place for some of our most well-established medicines. I think this is the main way that we can help loosen the economic burden on the NHS.

When it comes to worldwide access to medication, there are a lot of disparities between different countries. What is the pharmaceutical industry doing to tackle this?

We use a tiered pricing model which ensures that if you live in one of the poorest countries in the world and there’s a medicine available that you could benefit from and your country has the healthcare infrastructure to deliver that treatment, you will be given access to it.

I can’t speak on behalf of other pharmaceutical companies, but I wouldn’t be surprised if we weren’t the only ones doing this. Our global pricing model is something that we are profoundly proud of, and something that is here to stay.

Dr. Janssen was the founder of Janssen. How is the work that Janssen are doing today contributing to his legacy?

Dr. Paul Janssen lived by the following words: “Patients are waiting”. I think that everyone working at Janssen believes in this. Patients are at the heart of everything we do and that’s his legacy.

Dr. Janssen was a founding father in medicines for mental health, and he believed that those patients deserved treatments that work. Mental health disorders are notoriously difficult to treat, and yet we are still in this disease area because if it was important for Dr. Janssen, it’s important to us.

Patients have always come first at Janssen – this ethos is reflected in the Johnson & Johnson Credo and is evidenced in our company each day.

For every business decision we make, we ask, is this the right thing to be doing for our patients? If the answer is no, or I’m not sure, then there’s a much deeper discussion to be had.

Over the next 100 years, how do you think patient care and the role of the clinician will change?

I think everything will change. From the way that healthcare is delivered to the way we view health and disease in general, all of it will change.

At the moment, the older population are most in need of healthcare resources. However, broadly speaking, they aren’t very comfortable with technology.

This means we aren’t there yet with making technologies such as healthcare apps a part of the NHS, and we won’t be for a while. But, as the millennial generation grows up, their ability to use technology will allow a fundamental shift in the way we deliver care.

The NHS will need to go beyond handing out pills to keep the population healthy and start moving towards technologies that can help you manage your overall health and wellbeing. This could be an app, or a wearable, for example.

The way you think about it today will be fundamentally different to the way we will think about it 10 years, 20 years, 50 years and 70 years’ time.

Clinicians are used to delivering medical care a certain way. They look for specific symptoms and treat the underlying condition whilst doing no harm. In the future, clinicians will need to develop a more holistic approach to care that takes into account the wellbeing of the patient from many different standpoints.

This all contributes to the linking together of the health and social care systems by the UK government. It’s about caring for a patient throughout their entire life. The technology is already there in some ways, but there needs to be a cultural shift in clinicians, patients, all of us. This will be the biggest barrier but could also be the biggest enabler.

A major step towards this will be patient empowerment. People are tracking the number of likes they get on pictures they upload to social media all the time. If they were given the technology to track their own health too, they would be more informed and more empowered to make lifestyle changes that will improve their overall health.

We’re already seeing this with FitBits and health apps, so it’s already happening on some level.

Patients who are informed and empowered have less interaction with the healthcare system. Treating patients who have multiple co-morbidities and who are incredibly ill is costly and often it is too late to reverse most of the damage. By monitoring the health of patients early on, physicians and patients themselves can intervene before it gets serious.

I think the future has the potential to be really exciting for healthcare in the UK, however, I am concerned about the required cultural shift.

We shouldn’t underestimate the significant changes that must take place – from how people think about themselves and their health to the shift needed in the health system, technology, and medicine – everything will eventually need to evolve.

About Jennifer Lee

“Having joined the company back in 2012, Jennifer Lee is the Director of Health Economics, Market Access, Reimbursement & Advocacy at Janssen UK, the pharmaceutical company of Johnson & Johnson. As part of her role, she has been working in partnership with healthcare systems, continually seeking to improve the way products are delivered in collaboration with regulators and governments.”

Tagged with:

About author

Related Articles